Asset Publisher

vp-0004

print Print Back Back

Adcetris® (brentuximab vedotin)

Policy Number: VP-0004

Intravenous

 

Last Review Date: 12/07/2023

Date of Origin: 02/28/2012

Dates Reviewed: 06/2012, 09/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 04/2018, 09/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 06/2020, 09/2020, 12/2020, 03/2021, 06/2021, 09/2021, 12/2021, 03/2022, 06/2022, 09/2022, 12/2022, 03/2023, 06/2023, 09/2023, 12/2023

FOR PEEHIP Members Only -Coverage excludes the provider-administered medication(s) outlined in this drug policy from being accessed through a specialty pharmacy. It must be obtained through buy and bill.

  1. Length of Authorization 1,5,7,15,18,21

Coverage will be provided for 6 months and may be renewed (unless otherwise specified).

  • Treatment of previously untreated Pediatric Classical Hodgkin Lymphoma (cHL) as a component of Bv-AVE-PC (brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) has a maximum of 5 doses.
  • Pediatric cHL as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin) has a maximum of 2 cycles (6 doses).
  • Pediatric cHL as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine) has a maximum of 4 cycles (8 doses).
  • Pediatric and Adult cHL in combination with nivolumab has a maximum of 4 doses.
  • Pediatric and Adult cHL in combination with bendamustine has a maximum of 6 doses.
  • Adult cHL in combination with ifosfamide, carboplatin, and etoposide (ICE) has a maximum of 4 doses.
  • Adult cHL post-auto HSCT, Primary Cutaneous Lymphomas, and Pediatric cHL (excluding use with Bv-AVE-PC, AEPA, CAPDAC, nivolumab, or bendamustine) has a maximum of 16 doses.
  • Treatment of previously untreated Adult Stage III or IV cHL in combination with AVD (doxorubicin, vinblastine, and dacarbazine) has a maximum of 12 doses.
  • Treatment of previously untreated Peripheral T-Cell Lymphomas (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) has a maximum of 8 doses.
  • Adjuvant treatment of Breast-Implant Associated Anaplastic Large Cell Lymphoma (BIA- ALCL) has a maximum of 6 doses.
  1. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

  • Adcetris 50 mg single-dose vial: 9 vials every 28 days

B. Max Units (per dose and over time) [HCPCS Unit]:

   Classical Hodgkin Lymphoma:

  • 450 billable units every 28 days

   Primary Cutaneous Lymphomas:

  • 200 billable units every 21 days for 16 doses

   Previously Untreated PTCL

  • 200 billable units every 21 days for 8 doses

   Breast-Implant Associated Anaplastic Large Cell Lymphoma (ALCL) and all other indications:

  • 200 billable units every 21 days
  1. Initial Approval Criteria 1

Coverage is provided in the following conditions:

  • Patient is at least 18 years of age (unless otherwise specified); AND

Universal Criteria 1

    • Patient must not be receiving concomitant bleomycin; AND
    • Patient does not have severe renal impairment (i.e., CrCl <30 mL/min); AND
    • Patient does not have moderate or severe hepatic impairment (Child-Pugh B or C); AND
    • Patient has CD30-positive disease; AND

Adult Classic Hodgkin Lymphoma (cHL) † Ф 1,2,4,12-14

    • Used as single agent therapy; AND
      • Used as consolidation/maintenance therapy post-autologous hematopoietic stem cell transplant (auto-HSCT) in patients at high risk* for relapse or progression † ‡; OR
      • Patient has relapsed disease after failure of auto-HSCT or after failure of at least 2 (two) prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ; OR
      • Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ; OR
      • Used as palliative therapy for relapsed or refractory disease ; AND
        • Patient is > 60 years of age; OR
        • Patient has poor performance status; OR
        • Patient has substantial comorbidities; OR
    • Used in combination with bendamustine; AND
      • Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ; OR
    • Used in combination with nivolumab; AND
  • Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ; OR
    • Used in combination with dacarbazine; AND
      • Used as primary treatment in patients with low ejection fraction ; AND
        • Patient is > 60 years of age; OR
        • Patient has poor performance status; OR
        • Patient has substantial comorbidities; OR
    • Used in combination with ifosfamide, carboplatin, and etoposide (ICE); AND
      • Used as subsequent systemic therapy (if not previously used) for relapsed or refractory disease ; OR
    • Used in combination with doxorubicin, vinblastine, and dacarbazine (AVD); AND
      • Used as initial therapy for previously untreated stage III or IV disease ; OR
      • Used as primary treatment for stage I-II unfavorable disease ; AND
        • Patient is > 60 years of age; OR
        • Patient has poor performance status; OR
        • Patient has substantial comorbidities

*High risk for relapse or progression may be defined as:

  • Refractory disease, disease relapse within 12 months, or relapse ≥12 months with extranodal disease following frontline therapy OR 2 or more of the following: remission duration <1 year, extranodal involvement, FDG-PET+ response at time of transplant, B symptoms, and/or >1 second-line/subsequent therapy regimen

Pediatric Classic Hodgkin Lymphoma (cHL) † Ф 1,2,24

  • Patient is ≤ 18 years of age*; AND
      • Used as re-induction or subsequent therapy (if not previously used); AND
      • Patient has relapsed or refractory disease; AND
      • Used in combination with bendamustine, nivolumab, or gemcitabine; AND
        • Used in patients heavily pretreated with platinum or anthracycline-based chemotherapy; OR
        • Used if a decrease in cardiac function is observed; OR
    • Used as maintenance therapy following high-dose therapy and autologous stem cell rescue (HDT/ASCR); AND
      • Used as a single agent for relapsed or refractory high-risk disease (i.e., progressive disease, refractory disease, or relapse within 1 year of original diagnosis); OR
    • Used as primary therapy in patients with high risk disease**; AND
  • Used as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin) regimen; OR
  • Used as a component of Bv-AVE-PC (brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) ; AND
        • Patient is at least 2 years of age; OR
    • Used as additional treatment following primary treatment with AEPA regimen in patients with high risk disease**; AND
  • Used as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine) regimen

*Pediatric Hodgkin Lymphoma may be applicable to adolescent and young adult (AYA) patients up to the age of 39 years.

**High risk disease may be defined as: Stage IIB with bulk or E-lesions (involvement of extra-lymphatic tissue), Stage IIIA with bulk AND E-lesions, or Stage IIIB or IV disease.

Pediatric Aggressive Mature B-Cell Lymphomas (Primary Mediastinal Large B-Cell Lymphoma) ‡ 2,21

  • Patient is ≤ 18 years of age*; AND
  • Used in combination with nivolumab or pembrolizumab; AND
  • Used as consolidation/additional therapy if a partial response was achieved after therapy for relapsed or refractory disease

*Pediatric Aggressive Mature B-Cell Lymphoma may be applicable to adolescent and young adult (AYA) patients older than 18 years of age and less than 39 years of age, who are treated in the pediatric oncology setting.

T-Cell Lymphomas 1-3,15,16

    • Peripheral T-Cell Lymphomas (PTCL)
    • Used as a single agent for relapsed or refractory disease OR as initial palliative intent therapy for one of the following:
              • Systemic Anaplastic Large Cell Lymphoma (sALCL) Ф
              • Peripheral T-Cell Lymphoma (PTCL) not otherwise specified Ф
              • Angioimmunoblastic T-cell Lymphoma (AITL) Ф; OR
      • Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) as initial therapy for previously untreated:
              • Systemic Anaplastic Large Cell Lymphoma (sALCL) Ф
              • Peripheral T-Cell Lymphoma (PTCL) not otherwise specifiedФ
              • Angioimmunoblastic T-cell Lymphoma (AITL) Ф
              • Enteropathy-Associated T-cell Lymphoma (EATL) Ф
              • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL)
              • Nodal Peripheral T-cell Lymphoma with TFH phenotype (PTCL, TFH)
              • Follicular T-cell Lymphoma (FTCL)
    • Breast-Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
      • Used as adjuvant therapy as a single agent or in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); AND
  • Patient has localized disease to the capsule, implant, or breast with residual disease following an incomplete excision or partial capsulectomy, if either node positive or radiation therapy is not feasible; OR
  • Patient has extended disease (stage II-IV); OR
      • Used as subsequent therapy for relapsed or refractory disease as a single agent
    • Adult T-Cell Leukemia/Lymphoma Ф
      • Used as a single agent; AND
      • Used as subsequent therapy for non-responders to first-line therapy for acute or lymphoma subtypes; OR
    • Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); AND
      • Used as first-line therapy for acute or lymphoma subtypes; OR
      • Used as continued treatment in responders to first-line therapy for acute or lymphoma subtypes; OR
      • Used as subsequent therapy for non-responders to first-line therapy for chronic/smoldering subtype
    • Extranodal NK/T-Cell Lymphomas Ф
      • Used as a single agent for relapsed or refractory disease; AND
      • Used following additional therapy with an alternate combination chemotherapy regimen (asparaginase-based) not previously used
    • Hepatosplenic T-Cell Lymphoma
      • Used as single-agent therapy; AND
      • Used for refractory disease as subsequent therapy after progression on 2 (two) first-line therapy regimens

Primary Cutaneous Lymphomas 1,2,17

    • Mycosis Fungoides (MF) † Ф/Sezary Syndrome (SS)
      • Used as single agent systemic therapy; AND
      • Used as primary therapy (excluding use in patients with stage IA disease); OR
      • Used as subsequent therapy
    • Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders ‡ Ф
      • Used as a single agent; AND
      • Patient has primary cutaneous anaplastic large cell lymphoma (pcALCL) Ф; OR
      • Patient has cutaneous ALCL with regional node (N1) (excludes systemic ALCL); OR
      • Patient has lymphomatoid papulosis (LyP) with extensive lesions that is relapsed or refractory to treatment options (e.g., clinical trial, observation, retreatment with primary treatment, or treatment with alternative regimen not used for primary treatment); OR
    • Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP); AND
      • Patient has cutaneous ALCL with regional node (N1) (excludes systemic ALCL)

B-Cell Lymphomas 2,11

    • Diffuse Large B-Cell Lymphoma (DLBCL), HIV-Related B-Cell Lymphomas (i.e., DLBCL, primary effusion lymphoma, or HHV8-positive DLBCL, not otherwise specified), or High Grade B-Cell Lymphomas
      • Used as a single agent as subsequent therapy if no intention to proceed to transplant; AND
      • Used for relapsed or refractory disease >12 months after completion of first-line therapy; OR
      • Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of first-line therapy*; OR 
      • Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease*
    • Monomorphic Post-Transplant Lymphoproliferative Disorders (PTLD)
      • Used as a single agent as subsequent therapy for B-cell type disease if no intention to proceed to transplant; AND
      • Used for relapsed or refractory disease >12 months after completion of initial treatment with chemoimmunotherapy; OR
      • Used for primary refractory disease (partial response, no response, or progression) or relapsed disease <12 months after completion of initial treatment with chemoimmunotherapy*; OR
      • Used as alternative systemic therapy (if not previously used) for relapsed/refractory disease*; OR
      • Used in combination with CHP (cyclophosphamide, doxorubicin, prednisone) for T-cell type disease

*Note: Only applies to patients in which there is no intention to proceed to CAR T-cell therapy.

FDA Approved Indication(s); Compendia Recommended Indication(s); Ф Orphan Drug

  1. Renewal Criteria 1

Coverage may be renewed based upon the following criteria:

    • Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; AND
    • Disease response with treatment defined by stabilization of disease or decrease in size of tumor or tumor spread; AND
    • Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: peripheral neuropathy, anaphylaxis and infusion reactions, hematologic toxicities (thrombocytopenia, neutropenia, and anemia), serious infections, opportunistic infections, tumor lysis syndrome, hepatotoxicity, pulmonary toxicity, serious dermatologic reactions, gastrointestinal complications, uncontrolled hyperglycemia, etc.; AND
    • Patient has been evaluated for the presence of progressive multifocal leukoencephalopathy (PML) and has been found to be negative; AND

Pediatric cHL (in combination with Bv-AVE-PC, AEPA, CAPDAC, nivolumab, or bendamustine)

    • Coverage may not be renewed.

Pediatric cHL (all other treatment settings/regimens)

    • Patient has not exceeded a maximum of 16 (sixteen) doses.

Adult cHL (in combination with nivolumab, bendamustine, ICE)

    • Coverage may not be renewed.

Adult cHL (post-auto HSCT consolidation)

    • Patient has not exceeded a maximum of 16 (sixteen) doses.

Adult cHL (previously untreated stage III or IV in combination with AVD)

    • Patient has not exceeded a maximum of 12 (twelve) doses.

Primary Cutaneous Lymphomas

    • Patient has not exceeded a maximum of 16 (sixteen) doses.

Breast-Implant Associated Anaplastic Large Cell Lymphoma (ALCL) (adjuvant treatment)

    • Coverage may not be renewed.

Peripheral T-Cell Lymphomas (PTCL) (in combination with CHP)

    • Coverage may not be renewed.
  1. Dosage/Administration 1,5,7,15,18-21,23,25-31

Indication

Dose

Adult cHL

Previously untreated stage III or IV in combination with doxorubicin, vinblastine, and dacarbazine (AVD)

Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity

Consolidation post auto HSCT as a single agent

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity

Relapsed disease in combination with bendamustine

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 doses

Relapsed disease in combination with nivolumab

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 4 doses

Relapsed disease in combination with ifosfamide, carboplatin, and etoposide (ICE)

Administer 1.5 mg/kg (up to 150 mg) by intravenous infusion on day 1 and 8 every 3 weeks for a maximum of 4 doses

Primary therapy in combination with dacarbazine

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks in combination for 12 doses, followed by monotherapy until disease progression or unacceptable toxicity

All other treatment settings/regimens:

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity

Primary Cutaneous Lymphomas

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity

Pediatric cHL

Previously untreated high-risk disease in combination with Bv-AVE-PC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 5 doses

Primary therapy for high-risk disease as a component of AEPA (brentuximab vedotin, etoposide, prednisone, doxorubicin)

Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion on days 1, 8, 15 every 28 days for 2 cycles

Additional treatment as a component of CAPDAC (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine)

Administer 1.2 mg/kg (up to 120 mg) by intravenous infusion on days 1 and 8 every 21 days for 4 cycles

In combination with nivolumab

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 4 doses

In combination with bendamustine

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 doses

All other treatment settings/regimens

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity

Previously Untreated PTCL

In combination with cyclophosphamide, doxorubicin, and prednisone (CHP)

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks for a maximum of 6 to 8 doses

Breast-Implant Associated Anaplastic Large Cell Lymphoma (ALCL)

Adjuvant therapy

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until a maximum of 6 cycles, disease progression, or unacceptable toxicity

Relapsed/Refractory Disease

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity

All other indications

Administer 1.8 mg/kg (up to 180 mg) by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity

  1. Billing Code/Availability Information

HCPCS Code:

  • J9042 – Injection, brentuximab vedotin, 1 mg; 1 billable unit = 1 mg

NDC:

  • Adcetris 50 mg powder for injection in a single-dose vial: 51144-0050-xx
  1. References
  1. Adcetris [package insert]. Bothell, WA; Seattle Genetics, Inc; June 2023. Accessed October 2023.
  2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for brentuximab vedotin. National Comprehensive Cancer Network, 2023.  The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2023.
  3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) T-Cell Lymphomas. Version 1.2023.  National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2023.
  4. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hodgkin Lymphoma. Version 1.2024.  National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2023.
  5. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015; 33:3759-65.
  6. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095-3100.
  7. Alderuccio, JP., Desai, A., Yepes, M.M., et al. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma. Clin Case Rep 2018; 6(4): 634-637. Doi:10.1002/ccr3.1382.
  8. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. J Oncol Pract. 2018 Mar;14(3):e130-e136.
  9. Hematology/Oncology Pharmacy Association (Updated January 2022). Intravenous Cancer Drug Waste Issue Brief. Retrieved from https://www.hoparx.org/documents/65/HOPA_Drug_Waste_Issue_Brief_-_Updated_01.19.22_FINAL.pdf
  10. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. BMJ. 2016 Feb 29;352:i788.
  11. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) B-Cell Lymphomas. Version 6.2023.  National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2023.
  12. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma [published correction appears in N Engl J Med. 2018 Mar 1;378(9):878]. N Engl J Med. 2018;378(4):331-344.
  13. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862.
  14. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
  15. Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomized, phase 3 trial. Lancet. 2019;393(10168):229-240.
  16. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
  17. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomized, phase 3, multicentre trial. Lancet. 2017;390(10094):555-566.
  1. Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 Sep;19(9):1229-1238. Doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16.
  2. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26;125(9):1394-402. Doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.
  3. Chang VA, Wang HY, Reid EG. Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. Blood Adv. 2019 Mar 12;3(5):766-768. Doi: 10.1182/bloodadvances.2018026351.
  4. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Pediatric Aggressive Mature B-Cell Lymphomas. Version 1.2023.  National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2023.
  5. Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258.
  6. Zinzani PL, Santoro A, Gritti G, et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492.
  7. Castellino SM, Pei Q, Parsons SK, et al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660.
  8. Cole PD, Mauz-Körholz C, Mascarin M, et al. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. J Clin Oncol 2020;38:8013.
  9. Harker-Murray P, Mauz-Körholz C, Leblanc T,  et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. PMID: 36564047.
  10. O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicenter, single-arm, phase 1-2 trial. Lancet Oncol 2018;19:257-266.
  11. Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol 2021;8:e562-e571.
  12. Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood 2017;130:2829-2837.
  13. Friedberg JW, Forero-Torres A, Holkova B, et al. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma [abstract]. J Clin Oncol 2018;36 (Suppl 15):Abstract 7542.
  14. Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427-438

Appendix 1 – Covered Diagnosis Codes

ICD-10

ICD-10 Description

C81.10

Nodular sclerosis Hodgkin lymphoma, unspecified site

C81.11

Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck

C81.12

Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes

C81.13

Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes

C81.14

Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.15

Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.16

Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes

C81.17

Nodular sclerosis Hodgkin lymphoma, spleen

C81.18

Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites

C81.19

Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites

C81.20

Mixed cellularity Hodgkin lymphoma, unspecified site

C81.21

Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck

C81.22

Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes

C81.23

Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes

C81.24

Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.25

Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.26

Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes

C81.27

Mixed cellularity Hodgkin lymphoma, spleen

C81.28

Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites

C81.29

Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites

C81.30

Lymphocyte depleted Hodgkin lymphoma, unspecified site

C81.31

Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck

C81.32

Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes

C81.33

Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes

C81.34

Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.35

Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.36

Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes

C81.37

Lymphocyte depleted Hodgkin lymphoma, spleen

C81.38

Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites

C81.39

Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites

C81.40

Lymphocyte-rich Hodgkin lymphoma, unspecified site

C81.41

Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck

C81.42

Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes

C81.43

Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes

C81.44

Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.45

Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.46

Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes

C81.47

Lymphocyte-rich Hodgkin lymphoma, spleen

C81.48

Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites

C81.49

Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites

C81.70

Other Hodgkin lymphoma unspecified site

C81.71

Other Hodgkin lymphoma lymph nodes of head, face, and neck

C81.72

Other Hodgkin lymphoma intrathoracic lymph nodes

C81.73

Other Hodgkin lymphoma intra-abdominal lymph nodes

C81.74

Other Hodgkin lymphoma lymph nodes of axilla and upper limb

C81.75

Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb

C81.76

Other Hodgkin lymphoma intrapelvic lymph nodes

C81.77

Other Hodgkin lymphoma spleen

C81.78

Other Hodgkin lymphoma lymph nodes of multiple sites

C81.79

Other Hodgkin lymphoma extranodal and solid organ sites

C81.90

Hodgkin lymphoma, unspecified, unspecified site

C81.91

Hodgkin lymphoma, unspecified, lymph nodes of head, face and neck

C81.92

Hodgkin lymphoma, unspecified, intrathoracic lymph nodes

C81.93

Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes

C81.94

Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb

C81.95

Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb

C81.96

Hodgkin lymphoma, unspecified, intrapelvic lymph nodes

C81.97

Hodgkin lymphoma, unspecified, spleen

C81.98

Hodgkin lymphoma, unspecified, lymph nodes of multiple sites

C81.99

Hodgkin lymphoma, unspecified, extranodal and solid organ sites

C83.30

Diffuse large B-cell lymphoma unspecified site

C83.31

Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck

C83.32

Diffuse large B-cell lymphoma intrathoracic lymph nodes

C83.33

Diffuse large B-cell lymphoma intra-abdominal lymph nodes

C83.34

Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb

C83.35

Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb

C83.36

Diffuse large B-cell lymphoma intrapelvic lymph nodes

C83.37

Diffuse large B-cell lymphoma, spleen

C83.38

Diffuse large B-cell lymphoma lymph nodes of multiple sites

C83.39

Diffuse large B-cell lymphoma extranodal and solid organ sites

C83.80

Other non-follicular lymphoma, unspecified site

C83.81

Other non-follicular lymphoma, lymph nodes of head, face and neck

C83.82

Other non-follicular lymphoma, intrathoracic lymph nodes

C83.83

Other non-follicular lymphoma, intra-abdominal lymph nodes

C83.84

Other non-follicular lymphoma, lymph nodes of axilla and upper limb

C83.85

Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb

C83.86

Other non-follicular lymphoma, intrapelvic lymph nodes

C83.87

Other non-follicular lymphoma, spleen

C83.88

Other non-follicular lymphoma, lymph nodes of multiple sites

C83.89

Other non-follicular lymphoma, extranodal and solid organ sites

C83.90

Non-follicular (diffuse) lymphoma, unspecified site

C83.91

Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck

C83.92

Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes

C83.93

Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes

C83.94

Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb

C83.95

Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb

C83.96

Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes

C83.97

Non-follicular (diffuse) lymphoma, unspecified spleen

C83.98

Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites

C83.99

Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites

C84.00

Mycosis fungoides, unspecified site

C84.01

Mycosis fungoides, lymph nodes of head, face and neck

C84.02

Mycosis fungoides, intrathoracic lymph nodes

C84.03

Mycosis fungoides, intra-abdominal lymph nodes

C84.04

Mycosis fungoides, lymph nodes of axilla and upper limb

C84.05

Mycosis fungoides, lymph nodes of inguinal region and lower limb

C84.06

Mycosis fungoides, intrapelvic lymph nodes

C84.07

Mycosis fungoides, spleen

C84.08

Mycosis fungoides, lymph nodes of multiple sites

C84.09

Mycosis fungoides, extranodal and solid organ sites

C84.10

Sézary disease, unspecified site

C84.11

Sézary disease, lymph nodes of head, face, and neck

C84.12

Sézary disease, intrathoracic lymph nodes

C84.13

Sézary disease, intra-abdominal lymph nodes

C84.14

Sézary disease, lymph nodes of axilla and upper limb

C84.15

Sézary disease, lymph nodes of inguinal region and lower limb

C84.16

Sézary disease, intrapelvic lymph nodes

C84.17

Sézary disease, spleen

C84.18

Sézary disease, lymph nodes of multiple sites

C84.19

Sézary disease, extranodal and solid organ sites

C84.40

Peripheral T-cell lymphoma, not classified, unspecified site

C84.41

Peripheral T-cell lymphoma, not classified, lymph nodes of head, face and neck

C84.42

Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes

C84.43

Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes

C84.44

Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb

C84.45

Peripheral T-cell lymphoma, not classified, lymph n odes of inguinal region of lower limb

C84.46

Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes

C84.47

Peripheral T-cell lymphoma, not classified, spleen

C84.48

Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites

C84.49

Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites

C84.60

Anaplastic large cell lymphoma, ALK-positive, unspecified site

C84.61

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face and neck

C84.62

Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes

C84.63

Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes

C84.64

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb

C84.65

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb

C84.66

Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes

C84.67

Anaplastic large cell lymphoma, ALK-positive, spleen

C84.68

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites

C84.69

Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites

C84.7A

Anaplastic large cell lymphoma, ALK-negative, breast

C84.70

Anaplastic large cell lymphoma, ALK-negative, unspecified site

C84.71

Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face and neck

C84.72

Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes

C84.73

Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes

C84.74

Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb

C84.75

Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb

C84.76

Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes

C84.77

Anaplastic large cell lymphoma, ALK-negative, spleen

C84.78

Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites

C84.79

Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites

C84.90

Mature T/NK-cell lymphomas, unspecified site

C84.91

Mature T/NK-cell lymphomas, lymph nodes of head, face, and neck

C84.92

Mature T/NK-cell lymphomas, intrathoracic lymph nodes

C84.93

Mature T/NK-cell lymphomas, intra-abdominal lymph nodes

C84.94

Mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb

C84.95

Mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb

C84.96

Mature T/NK-cell lymphomas, intrapelvic lymph nodes

C84.97

Mature T/NK-cell lymphomas, spleen

C84.98

Mature T/NK-cell lymphomas, lymph nodes of multiple sites

C84.99

Mature T/NK-cell lymphomas, extranodal and solid organ sites

C84.Z0

Other mature T/NK-cell lymphomas, unspecified site

C84.Z1

Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck

C84.Z2

Other mature T/NK-cell lymphomas, intrathoracic lymph nodes

C84.Z3

Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes

C84.Z4

Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb

C84.Z5

Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb

C84.Z6

Other mature T/NK-cell lymphomas, intrapelvic lymph nodes

C84.Z7

Other mature T/NK-cell lymphomas, spleen

C84.Z8

Other mature T/NK-cell lymphomas, lymph nodes of multiple sites

C84.Z9

Other mature T/NK-cell lymphomas, extranodal and solid organ sites

C85.10

Unspecified B-cell lymphoma unspecified site

C85.11

Unspecified B-cell lymphoma lymph nodes of head, face, and neck

C85.12

Unspecified B-cell lymphoma intrathoracic lymph nodes

C85.13

Unspecified B-cell lymphoma intra-abdominal lymph nodes

C85.14

Unspecified B-cell lymphoma lymph nodes of axilla and upper limb

C85.15

Unspecified B-cell lymphoma lymph nodes of inguinal region and lower limb

C85.16

Unspecified B-cell lymphoma intrapelvic lymph nodes

C85.17

Unspecified B-cell lymphoma spleen

C85.18

Unspecified B-cell lymphoma lymph nodes of multiple sites

C85.19

Unspecified B-cell lymphoma extranodal and solid organ sites

C85.20

Mediastinal (thymic) large B-cell lymphoma, unspecified site

C85.21

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck

C85.22

Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes

C85.23

Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes

C85.24

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb

C85.25

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb

C85.26

Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes

C85.27

Mediastinal (thymic) large B-cell lymphoma, spleen

C85.28

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites

C85.29

Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites

C85.80

Other specified types of non-Hodgkin lymphoma, unspecified site

C85.81

Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck

C85.82

Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes

C85.83

Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes

C85.84

Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb

C85.85

Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb

C85.86

Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes

C85.87

Other specified types of non-Hodgkin lymphoma, spleen

C85.88

Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites

C85.89

Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites

C86.0

Extranodal NK/T-cell lymphoma, nasal type

C86.1

Hepatosplenic T-cell lymphoma

C86.2

Enteropathy-type (intestinal) T-cell lymphoma

C86.5

Angioimmunoblastic T-cell lymphoma

C86.6

Primary cutaneous CD30-positive T-cell proliferations

C91.50

Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission

C91.51

Adult T-cell lymphoma/leukemia (HTLV-1-associated) in remission

C91.52

Adult T-cell lymphoma/leukemia (HTLV-1-associated) in relapse

D47.Z1

Post-transplant lymphoproliferative disorder (PTLD)

Z85.71

Personal history of Hodgkin lymphoma

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction

Applicable State/US Territory

Contractor

E (1)

CA, HI, NV, AS, GU, CNMI

Noridian Healthcare Solutions, LLC

F (2 & 3)

AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ

Noridian Healthcare Solutions, LLC

5

KS, NE, IA, MO

Wisconsin Physicians Service Insurance Corp (WPS)

6

MN, WI, IL

National Government Services, Inc. (NGS)

H (4 & 7)

LA, AR, MS, TX, OK, CO, NM

Novitas Solutions, Inc.

8

MI, IN

Wisconsin Physicians Service Insurance Corp (WPS)

N (9)

FL, PR, VI

First Coast Service Options, Inc.

J (10)

TN, GA, AL

Palmetto GBA, LLC

M (11)

NC, SC, WV, VA (excluding below)

Palmetto GBA, LLC

L (12)

DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)

Novitas Solutions, Inc.

K (13 & 14)

NY, CT, MA, RI, VT, ME, NH

National Government Services, Inc. (NGS)

15

KY, OH

CGS Administrators, LLC

 

 

 

 

ADCETRIS® (brentuximab vedotin) Prior Auth Criteria
Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2023, Magellan Rx Management

White MRx.PNG